Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Eugene Teoh, MBBS, MRCP, from the University of Oxford, Oxford, UK, introduces a pre-planned analysis of the FALCON trial (NCT02578940), which investigated the influence of 18F-fluciclovine PET/CT imaging for the management of prostate cancer patients considered for salvage curative therapy, following a first biochemical recurrence of the cancer. Dr Teoh discusses how the endpoint of the trial was determined by the percentage of patients with a change in their management plan. Results from the FALCON trial have shown promise, even in a population with low median prostate-specific antigen expression. Dr Teoh highlights the importance of using spatial information in practice to modify management plans, in order to improve patient outcomes.
FALCON: radiopharmaceuticals for the management of recurrent prostate cancer
